C Marchesi1, P Ossola2, A Amerio3, B D Daniel4, M Tonna5, C De Panfilis6. 1. Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy; Treatment of Affective Disorders in Perinatal Period Unit, University Hospital of Parma, Parma, Italy; Department of Mental Health, Local Healthy Service of Parma, Parma, Italy. Electronic address: carlo.marchesi@unipr.it. 2. Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy. Electronic address: paolo.ossola@unipr.it. 3. Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy; Mood Disorders Program, Tufts Medical Center, Boston, MA, USA. Electronic address: andrea.amerio@studenti.unipr.it. 4. Treatment of Affective Disorders in Perinatal Period Unit, University Hospital of Parma, Parma, Italy; Department of Mental Health, Local Healthy Service of Parma, Parma, Italy. Electronic address: daniel.benjamindaniel@gmail.com. 5. Department of Mental Health, Local Healthy Service of Parma, Parma, Italy. Electronic address: mtonna@ausl.pr.it. 6. Department of Neuroscience, Psychiatry Unit, University of Parma, Parma, Italy; Treatment of Affective Disorders in Perinatal Period Unit, University Hospital of Parma, Parma, Italy; Department of Mental Health, Local Healthy Service of Parma, Parma, Italy. Electronic address: chiara.depanfilis@unipr.it.
Abstract
BACKGROUND: In the last few decades, there has been a growing interest in anxiety disorders (AnxD) in the perinatal period. Although AnxD are diagnosed in 4-39% of pregnant women and in up to 16% of women after delivery, evidence on their clinical management is limited. METHODS: A systematic review was conducted on pharmacological and non-pharmacological treatment of AnxD in the perinatal period. Relevant papers published from January 1st 2015 were identified searching the electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library. RESULTS: 18 articles met inclusion criteria. Selected studies supported the use of cognitive-behavioural therapy (CBT) for obsessive-compulsive disorder (OCD), panic disorder (PD) and specific phobia both in pregnancy and postpartum. Selective serotonin reuptake inhibitors (SSRIs) led to significant OCD and PD improvement both in pregnancy and postpartum with no side effects for the babies. In the largest clinical sample to date, 65% of postpartum patients who entered the open-label trial of fluvoxamine (up to 300mg/day) experienced a 30% or greater decrease in the total score of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). During pregnancy, SSRIs and tricyclic antidepressants (TCAs) led to remission of panic symptoms and healthy outcomes for the babies. LIMITATIONS: Study design, mostly case reports, and enrolment of subjects mainly from outpatient specialty units might have limited community-wide generalisability. CONCLUSIONS: Keeping in mind the scantiness and heterogeneity of the available literature, the best interpretation of the available evidence appears to be that CBT should be the first treatment offered to pregnant and breastfeeding women with AnxD. However SSRIs can represent a first line treatment strategy, and not exclusively in cases where AnxD is refractory to CBT.
BACKGROUND: In the last few decades, there has been a growing interest in anxiety disorders (AnxD) in the perinatal period. Although AnxD are diagnosed in 4-39% of pregnant women and in up to 16% of women after delivery, evidence on their clinical management is limited. METHODS: A systematic review was conducted on pharmacological and non-pharmacological treatment of AnxD in the perinatal period. Relevant papers published from January 1st 2015 were identified searching the electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library. RESULTS: 18 articles met inclusion criteria. Selected studies supported the use of cognitive-behavioural therapy (CBT) for obsessive-compulsive disorder (OCD), panic disorder (PD) and specific phobia both in pregnancy and postpartum. Selective serotonin reuptake inhibitors (SSRIs) led to significant OCD and PD improvement both in pregnancy and postpartum with no side effects for the babies. In the largest clinical sample to date, 65% of postpartum patients who entered the open-label trial of fluvoxamine (up to 300mg/day) experienced a 30% or greater decrease in the total score of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). During pregnancy, SSRIs and tricyclic antidepressants (TCAs) led to remission of panic symptoms and healthy outcomes for the babies. LIMITATIONS: Study design, mostly case reports, and enrolment of subjects mainly from outpatient specialty units might have limited community-wide generalisability. CONCLUSIONS: Keeping in mind the scantiness and heterogeneity of the available literature, the best interpretation of the available evidence appears to be that CBT should be the first treatment offered to pregnant and breastfeeding women with AnxD. However SSRIs can represent a first line treatment strategy, and not exclusively in cases where AnxD is refractory to CBT.
Authors: Emily J Fawcett; Nichole Fairbrother; Megan L Cox; Ian R White; Jonathan M Fawcett Journal: J Clin Psychiatry Date: 2019-07-23 Impact factor: 4.384
Authors: Derrick Ssewanyana; Julia A Knight; Stephen G Matthews; Jody Wong; Nadya Adel Khani; Jennifer Lye; Kellie E Murphy; Kim Foshay; Justin Okeke; Stephen J Lye; Rayjean J Hung Journal: Pediatr Res Date: 2022-03-14 Impact factor: 3.756
Authors: Emily R Dworkin; Laura Zambrano-Vazquez; Sarah R Cunningham; Samantha L Pittenger; Julie A Schumacher; Paul R Stasiewicz; Scott F Coffey Journal: Rural Ment Health Date: 2017-06-05
Authors: Y C Janardhan Reddy; A Shyam Sundar; Janardhanan C Narayanaswamy; Suresh Bada Math Journal: Indian J Psychiatry Date: 2017-01 Impact factor: 1.759